Artisan Partners Limited Partnership Lowers Holdings in Insulet Corporation $PODD

Artisan Partners Limited Partnership trimmed its position in Insulet Corporation (NASDAQ:PODD) by 1.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 659,057 shares of the medical instruments supplier’s stock after selling 9,789 shares during the quarter. Artisan Partners Limited Partnership’s holdings in Insulet were worth $187,330,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Insulet by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock worth $2,715,651,000 after buying an additional 87,845 shares during the period. State Street Corp lifted its holdings in shares of Insulet by 2.1% in the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after buying an additional 65,317 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Insulet by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after buying an additional 41,019 shares during the period. Norges Bank purchased a new stake in shares of Insulet in the 4th quarter worth $300,794,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Insulet by 3.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 806,119 shares of the medical instruments supplier’s stock worth $229,131,000 after buying an additional 29,690 shares during the period.

Insulet Trading Down 0.3%

Shares of NASDAQ:PODD opened at $147.69 on Wednesday. The business’s 50-day moving average is $167.67 and its 200 day moving average is $229.40. Insulet Corporation has a 1 year low of $140.63 and a 1 year high of $354.88. The firm has a market capitalization of $10.23 billion, a P/E ratio of 34.35, a P/E/G ratio of 1.17 and a beta of 1.13. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s revenue was up 33.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts predict that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Sanford C. Bernstein reduced their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Truist Financial reduced their price target on Insulet from $250.00 to $219.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Barclays reduced their price target on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research report on Thursday, May 7th. Wall Street Zen raised Insulet from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Robert W. Baird reduced their price target on Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $240.78.

Insider Buying and Selling at Insulet

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.36% of the company’s stock.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.